FIELD: medicine, gene engineering.
SUBSTANCE: the present innovation deals with introducing either protein factor or gene coding this protein factor for juvenile animal, where protein factor is being either epidermal growth factor, tumor growth factor-alpha, heparin-binding growth factor or amphiregulin. Or the method deals with introduction of a gene coding protein factor into early embryonic germ line or fertilized animal ovicell, for its transformation. The methods suggested enable to obtain animals with stable sensomotor and behavioral disorders. Animals obtained due to these techniques could be applied in medicine as schizophrenic model animal with sensomotor and behavioral disorders.
EFFECT: higher efficiency.
8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF CARBAMATES FOR PREVENTING OR TREATING PSYCHOTIC DISORDERS | 2002 |
|
RU2302240C2 |
| DERIVATIVES OF 7-FLUORO-8-CHLORO-5H-DIBENZO [B, E] [1, 4] DIAZEPINE AND THEIR APPLICATION | 2014 |
|
RU2610169C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FUNCTIONAL MENTAL DISORDERS | 2016 |
|
RU2667954C2 |
| ACTIVE SOLUBLE ISOFORMS OF NEUREGULIN, WHICH CARRY POST-TRANSLATION MODIFICATIONS | 2008 |
|
RU2491955C2 |
| PSYCHOTIC DISORDER SIMULATION METHOD | 2004 |
|
RU2366464C2 |
| DIAGNOSTIC KIT FOR DETECTING SCHIZOPHRENIA | 2001 |
|
RU2216741C1 |
| APPLICATION OF N-DISMETILKLOSAPINE FOR HUMAN NEUROPSYCHIATRIC DISEASES TREATMENT | 2004 |
|
RU2336879C2 |
| APPLICATION OF EPIDERMAL GROWTH FACTOR FOR MORPHOFUNCTIONAL RECOVERY OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY | 2007 |
|
RU2460536C2 |
| SELECTIVE INVERSE SEROTONIN 2A/2C RECEPTOR AGONISTS APPLICABLES AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2465267C2 |
| MEANS FOR TREATMENT AND PREVENTION OF SLEEP DISORDERS | 2014 |
|
RU2566713C1 |
